India drug industry says U.S.-led trade deal will raise prices

Reuters reports that leaders of India’s $15 billion pharmaceuticals industry, a major supplier of affordable generics to the world, have joined public health activists in criticizing a new U.S.-led trade deal they say will delay the arrival of new cheap drugs. Industry executives said provisions of the Trans-Pacific Partnership (TPP) deal struck earlier this month between 12 nations that shield new drug data from competitors would hurt their business in those nations.